AZD0585 Phase III Long-term Study in Japan

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 383 participants.

Also called NCT02463071

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 383 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02463071
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02463071. Randomized; double masking; primary purpose treatment. Start 2015-06-10 (actual); primary completion 2017-03-11 (actual). Results posted on 2018-10-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
AZD0585 Phase III Long-term Study in Japan
Condition
Hypertriglyceridemia
Intervention (Drug)
AZD0585
Intervention (Drug)
AZD0585 placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02463071
Content hash
127b9ed47d0939eb05b433f3e101c013651168eccd91e33f3a83cbe86ccafbbc